Dordaviprone
Small molecule
Evidence outlook
Approved: Glioma
Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.
track record: Weak signal
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
NCT02525692 NCT02525692 · Glioma This was an open-label study with no randomization and no control group, split into six small arms of 3 to 30 patients. Without a comparison group, the 6-month progression-free rates cannot show whether dordaviprone changed the course of the disease. Registry: NCT02525692 | 2 | Percent of Patients With Probability of Progression-Free Survival at 6 Months (Progression-free survival assessments were conducted 6 months following treatment initiation.) 2023-04-17 | Stopped early (terminated). Key figures are not recorded here. | Weak signal | link ↗ |
View 2 more trials
NCT03295396 NCT03295396 · Glioma This was an open-label, single-treatment study with no randomization and no control group, in 73 patients. Tumour responses were counted, but without a comparison group the study cannot show how much of the effect is due to dordaviprone. Registry: NCT03295396 | 2 | Number of Patients With Overall Response (From first dose of study treatment through study completion, an average of 1 year) 2022-12-31 | Stopped early (terminated). Key figures are not recorded here. | Weak signal | link ↗ |
NCT03416530 NCT03416530 · Glioma Registry: NCT03416530 | 1 | RP2D (28 days) 2022-12-31 | Results not posted; external-source review pending | not yet graded | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 3 (2)
What this study did
What this study did
Phase 2 (11)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 1/2 (6)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 1 (8)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Competitive landscape
This drug's own stage for Glioma: Approved. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Dordaviprone: this drug | Approved | Small molecule | Mitochondrial caseinolytic protease P (ClpP), Dopamine D2 receptor | Weak signal | No reviewed efficacy summary in this indication | |
| Dabrafenib | Approved | Small molecule | BRAF V600E/V600K/V600D (also wild-type BRAF/CRAF) | not yet graded | No reviewed efficacy summary in this indication | |
| Temozolomide | Approved | Small molecule | DNA alkylation (O6-guanine) | Partial signal | NCT00626990: Overall survival: adjuvant temozolomide vs none, median 82.3 vs 46.9 months, hazard ratio 0.64 (95% CI 0.52 to 0.79), p<0.0001; concurrent temozolomide vs none, 66.9 vs 60.4 months, hazard ratio 0.97 (95% CI 0.73 to 1.28), p=0.76 (CT.gov posted results). | |
| Tovorafenib | Approved | Small molecule | Kinase Inhibitor | Weak signal | No reviewed efficacy summary in this indication | |
| Trametinib | Approved | Small molecule | MEK1/2 | not yet graded | No reviewed efficacy summary in this indication | |
| Luvometinib | Phase 3 | Small molecule | MEK1/2 | not yet graded | No reviewed efficacy summary in this indication | |
| Safusidenib | Phase 3 | Small molecule | Mutant IDH1 | not yet graded | No reviewed efficacy summary in this indication | |
| Abemaciclib (Verzenio) | Phase 2 | Small molecule | CDK4 and CDK6 | not yet graded | No reviewed efficacy summary in this indication | |
| Olutasidenib | Phase 2 | Small molecule | Mutant IDH1 | not yet graded | No reviewed efficacy summary in this indication | |
| Crelosidenib | Phase 1 | Small molecule | Mutant IDH1 and IDH2 | not yet graded | No reviewed efficacy summary in this indication | |
| Vebreltinib | Phase 1 | Small molecule | MET | not yet graded | No reviewed efficacy summary in this indication |
Upcoming events
(6 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Follow Dordaviprone to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.